Skip to main
LGND

Ligand Pharmaceuticals (LGND) Stock Forecast & Price Target

Ligand Pharmaceuticals (LGND) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ligand Pharmaceuticals is a sound investment choice, backed by strong financial performance and promising developments in their pipeline and recent acquisition. However, there are potential risks and challenges to consider, such as reliance on a few key products and the need for ongoing successful partnerships. The company's commitment to sustainability is also noteworthy.

Bears say

Ligand Pharmaceuticals is facing several risks that could negatively impact its stock, including potential declines in royalty revenue, dependence on Captisol sales, potential acquisition integration issues, and risks associated with drugs in development. With several pivotal data readouts and a Phase 4 study underway, there may be volatility in the near future for Travere's FILSPARI, although initial uptake has been strong. Additionally, while Ligand has made strides in diversity with two women on its board and senior management team, there is room for improvement in terms of gender representation.

Ligand Pharmaceuticals (LGND) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ligand Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ligand Pharmaceuticals (LGND) Forecast

Analysts have given Ligand Pharmaceuticals (LGND) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Ligand Pharmaceuticals (LGND) has a Strong Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $335.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $335.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ligand Pharmaceuticals (LGND)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.